Founded in 1977 and headquartered in Rockville, MD, Emmes is a global, tech-enabled full-service clinical research organization (CRO) platform dedicated to supporting the advancement of public health and biopharmaceutical innovation. The Company sits at the intersection of the public and private healthcare sectors with clients including biopharmaceutical companies, government agencies, foundations, academic institutions, and other non-profit organizations. Emmes supports the research efforts agencies such as the National Institutes of Health (NIH), Food and Drug Administration (FDA), Department of Defense (DOD) and more. The Company provides a full-service, scaled offering with a differentiated level of specialized skills across statistics, real world evidence, clinical safety & PV, regulatory, medical device management, and clinical research services across its customer base.
New Mountain’s investment in Emmes is the product of the firm’s multi-year sector “deep dive” in tech-enabled healthcare services companies that both lower costs and improve outcomes, which previously led to New Mountain’s investment in Cytel.